ライフサイエンスコーパス: megakaryopoiesis

1 suggesting FLI1 negatively regulates ETS1 in megakaryopoiesis.

2 d overexpression of ETS proteins in aberrant megakaryopoiesis.

3 pa J region (RBPJ) and caused abnormal fetal megakaryopoiesis.

4 LRP1, which is transiently expressed during megakaryopoiesis.

5 ed increased platelet counts and bone marrow megakaryopoiesis.

6 disorders that shed light on the process of megakaryopoiesis.

7 at 4 different loci of PEAR1 during in vitro megakaryopoiesis.

8 -) mice manifested splenomegaly and abnormal megakaryopoiesis.

9 n of the alphaIIb gene at high levels during megakaryopoiesis.

10 erentiation in vitro, but absent during late megakaryopoiesis.

11 or -2 as part of its essential role in early megakaryopoiesis.

12 vel role of PI3K and PKCzeta in steady-state megakaryopoiesis.

13 at they may be regulated coordinately during megakaryopoiesis.

14 ion, demonstrating that CBFA2 dosage affects megakaryopoiesis.

15 e at once several Sp1-dependent genes during megakaryopoiesis.

16 ly to share common regulatory domains during megakaryopoiesis.

17 hematopoietic growth factor that stimulates megakaryopoiesis.

18 s receptor (MPL) are important regulators of megakaryopoiesis.

19 the c-Mpl receptor, is a major regulator of megakaryopoiesis.

20 fects of thrombopoietin on these measures of megakaryopoiesis.

21 omprehensive and definitive understanding of megakaryopoiesis.

22 te, thus contributing little to steady-state megakaryopoiesis.

23 ms have distinct and specific roles in adult megakaryopoiesis.

24 -HPA-1a antibodies (F/NAIT sera) on in vitro megakaryopoiesis.

25 g an explanation for the observed defects in megakaryopoiesis.

26 stinct critical stages of erythropoiesis and megakaryopoiesis.

27 further reveal that miR-142 is critical for megakaryopoiesis.

28 five transcription factors key in regulating megakaryopoiesis.

29 study, we demonstrate a role for VEGFR-3 in megakaryopoiesis.

30 isms underlying MkP biology and more broadly megakaryopoiesis.

31 suggesting a regulatory role for VEGFR-3 in megakaryopoiesis.

32 ocytopenia, and (3) a novel role for XPO1 in megakaryopoiesis.

33 rrode the inhibitory effects of forskolin on megakaryopoiesis.

34 yte, and is specifically up regulated during megakaryopoiesis.

35 differences between fetal/neonatal and adult megakaryopoiesis.

36 hematopoietic progenitor cell expansion and megakaryopoiesis.

37 astic leukemia, and plays a critical role in megakaryopoiesis.

38 xpression of miR-146a has minimal effects on megakaryopoiesis.

39 uired for both definitive erythropoiesis and megakaryopoiesis.

40 thropoiesis but permitted granulopoiesis and megakaryopoiesis.

41 for hematopoietic stem cell maintenance and megakaryopoiesis.

42 verexpression of GATA-2 facilitates aberrant megakaryopoiesis.

43 sion was able to limit the effects of PF4 on megakaryopoiesis.

44 this receptor's importance in PF4's role in megakaryopoiesis.

45 TL1 and SGK2 dysregulated erythropoiesis and megakaryopoiesis, 2 lineages commonly affected in chroni

46 termediate progenitor populations in erythro-megakaryopoiesis, allowing for in-depth study of disorde

47 d in the bone marrow and spleen, with normal megakaryopoiesis and absence of myelofibrosis in histopa

48 ropose miR-125b-2 as a positive regulator of megakaryopoiesis and an oncomiR involved in the pathogen

49 ANKRD26 silencing during the late stages of megakaryopoiesis and blood platelet development.

50 nstrate an in vivo requirement for ZBP-89 in megakaryopoiesis and definitive erythropoiesis but not p

51 rated profound defects in erythropoiesis and megakaryopoiesis and deregulated expression of RUNX1 tar

52 uence of overexpression of c-myc oncogene on megakaryopoiesis and endomitosis in vivo, using transgen

53 Gata1, a key regulator of megakaryopoiesis and erythropoiesis, was decreased in St

54 Here, we investigated PAF-AH function during megakaryopoiesis and found that human CD34(+) cells accu

55 of the role of SDF-1 and TPO in normal human megakaryopoiesis and indicates the molecular basis of th

56 anding of PF4's negative paracrine effect in megakaryopoiesis and its potential clinical implications

57 logical and molecular pathways that regulate megakaryopoiesis and lead to platelet production.

58 providing insights into mechanisms of normal megakaryopoiesis and megakaryocytic abnormalities that a

59 t impaired erythroid potential, but enhanced megakaryopoiesis and myelopoiesis, recapitulating the ma

60 The mechanisms regulating megakaryopoiesis and platelet production (thrombopoiesis

61 d to thrombopoietin, specifically stimulates megakaryopoiesis and platelet production and reduces the

62 Decoding the pathways of megakaryopoiesis and platelet production should help rev

63 ion during endomitosis is crucial for normal megakaryopoiesis and platelet production.

64 for the role of RUNX1 haploinsufficiency in megakaryopoiesis and predisposition to AML.

65 ill increase our insight in the processes of megakaryopoiesis and proplatelet formation, and it may a

66 ifferentially regulated miRNAs during murine megakaryopoiesis and provide a useful new dataset for he

67 e findings reveal a unique role for STAT1 in megakaryopoiesis and provide new insights into how GATA-

68 ions establish a critical role for GATA-1 in megakaryopoiesis and raise the question as to how GATA-1

69 role of downstream mediators of NOTCH during megakaryopoiesis and report crosstalk between the NOTCH

70 DKN1A transcriptional axis in the control of megakaryopoiesis and reveal the lineage-selective inhibi

71 on pathway is required for regulating proper megakaryopoiesis and suggests that it is likely to funct

72 tant tool for the study of ex-vivo models of megakaryopoiesis and the production of functional platel

73 standing of the mechanisms underlying normal megakaryopoiesis and thrombopoiesis that can inform effo

74 nt into the molecular pathways that regulate megakaryopoiesis and thrombopoiesis.

75 ned whether FLI1 overexpression would affect megakaryopoiesis and thrombopoiesis.

76 t of Akt phosphorylation, itself controlling megakaryopoiesis and thrombopoiesis.

77 e to introduce the physiological pathways of megakaryopoiesis and to present landmark studies on acqu

78 iming, GATA2 plays an extensive role in late megakaryopoiesis as a transcriptional repressor at loci

79 s will be very useful for further studies of megakaryopoiesis as well as the elucidation of their gen

80 mal-derived factor 1 (SDF-1) in normal human megakaryopoiesis at the cellular and molecular levels an

81 tments and a shift of differentiation toward megakaryopoiesis at the expense of erythropoiesis.

82 pe zinc finger protein that is essential for megakaryopoiesis, binds to the amino-terminal finger of

83 Thrombopoietin (Tpo) is a major regulator of megakaryopoiesis both in vivo and in vitro.

84 s transcriptional complex regulates not only megakaryopoiesis but also alpha-granule generation and s

85 risomy of approximately 80% of Hsa21 perturb megakaryopoiesis but are insufficient to induce leukemia

86 strongly up-regulated during mouse and human megakaryopoiesis but not erythropoiesis.

87 1 mice resulted in a synergistic increase in megakaryopoiesis, but did not result in leukemia or a TM

88 et factor 4 (PF4) is a negative regulator of megakaryopoiesis, but its mechanism of action had not be

89 cells (ESCs), expression of GATA1s promoted megakaryopoiesis, but not erythropoiesis.

90 ed that Ikaros-deficient mice have increased megakaryopoiesis, but the molecular mechanism of this ph

91 al anti-HPA-1a antibodies can suppress fetal megakaryopoiesis by inducing early cell death and that t

92 udy, which suggests that this miRNA inhibits megakaryopoiesis cell-autonomously.

93 We conclude that the abnormal megakaryopoiesis characterizing ET accounts for a shorte

94 ion of hematopoietic stem cells and enhanced megakaryopoiesis, demonstrating reduced LNK function and

95 f MDS in the mouse and re-establishes normal megakaryopoiesis, erythropoiesis, BM function, and perip

96 e mechanisms by which cAMP signaling impairs megakaryopoiesis have never been elucidated.

97 aryocytes in hematopoietic tissues, studying megakaryopoiesis heavily relies on the availability of a

98 In human megakaryopoiesis, hereditary disorders of platelet produ

99 Some cytokines that stimulate megakaryopoiesis (IL-6, IL-11, leukemia inhibitory facto

100 Megakaryopoiesis in Bcl-x(Pf4Delta/Pf4Delta) Mcl-1(Pf4De

101 Prior studies have shown that EP stimulates megakaryopoiesis in BM cells from patients with acute my

102 rine embryonic fibroblast cells and enhanced megakaryopoiesis in bone marrow progenitor cells.

103 , tumor growth was associated with increased megakaryopoiesis in both model systems.

104 However, enhanced megakaryopoiesis in BUBR1(+/-) mice was not correlated w

105 egakaryocyte development as well as aberrant megakaryopoiesis in Gata1 mutant cells.

106 rescued multiple defects in Gata1-deficient megakaryopoiesis in mice, inducing polyploidization and

107 ribosomal deficiency contributes to impaired megakaryopoiesis in myeloproliferative neoplasms.

108 that G-CSF does not account for the residual megakaryopoiesis in T(-) mice.

109 le explanation for the observed increases in megakaryopoiesis in these mice.

110 Thus the effects of Tpo on megakaryopoiesis in vitro do not depend on cytokines tha

111 et factor 4 (PF4) is a negative regulator of megakaryopoiesis in vitro.

112 We have now examined whether PF4 regulates megakaryopoiesis in vivo by studying PF4 knockout mice a

113 lineage commitment during erythropoiesis and megakaryopoiesis in vivo.

114 activate ERK in vitro and support base-line megakaryopoiesis in vivo.

115 homolog and Forkhead Box class O factors on megakaryopoiesis in vivo.

116 he megakaryocyte lineage, several aspects of megakaryopoiesis, including progenitors, maturing megaka

117 Expression of Hmga2 enhanced megakaryopoiesis, increased extramedullary hematopoiesis

118 data suggest that CIB1 plays a dual role in megakaryopoiesis, initially by negatively regulating TPO

119 role for these Ezh2 target genes in altered megakaryopoiesis involved in MF.

120 Megakaryopoiesis is a 2-step differentiation process, re

121 Megakaryopoiesis is a complex, stepwise process that tak

122 Megakaryopoiesis is also defective during crisis.

123 he expression of megakaryocytic genes during megakaryopoiesis is controlled by specific transcription

124 the mechanism by which mutated CALR perturbs megakaryopoiesis is currently unresolved.

125 Megakaryopoiesis is greatly enhanced in Pf4-Cre/FAK-flox

126 These data demonstrate that Jak2 in terminal megakaryopoiesis is not required for PLT production, and

127 Megakaryopoiesis is the process by which hematopoietic s

128 tal liver also refute early suggestions that megakaryopoiesis is unaffected by the absence of c-Myb.

129 h progressively increases along normal human megakaryopoiesis, is decreased in platelets of patients

130 ation of Lyn kinase, a negative regulator of megakaryopoiesis, is severely attenuated in FAK-null meg

131 In megakaryopoiesis, loss of GATA-1 function produces compl

132 from four patients were used to investigate megakaryopoiesis, megakaryocyte morphology and platelet

133 in uncovering novel molecular mechanisms of megakaryopoiesis, modeling and correcting relevant disea

134 hese results demonstrate that the defects in megakaryopoiesis observed in FPD/AML are, in part, relat

135 Donor-derived megakaryopoiesis occurred at higher densities in the spl

136 Here we studied the in vitro megakaryopoiesis of 3 FPD/AML pedigrees.

137 Defective megakaryopoiesis of Fanca(-/-) cells is associated with

138 ene targeting, which led to normalization of megakaryopoiesis of the iPSCs in culture.

139 The dependence of megakaryopoiesis on critical thresholds of E2A expressio

140 n mediating the effects of Ex12 signaling on megakaryopoiesis or erythropoiesis.

141 f VEGFR-3 did not affect steady-state murine megakaryopoiesis or platelet counts significantly.

142 However, in Fli-1-/- mice, early megakaryopoiesis persists, and the expression of the ear

143 Megakaryopoiesis, platelet production, and platelet life

144 ukemia virus (MPL), a key regulator of adult megakaryopoiesis, play in prenatal platelet-forming line

145 l role for Pak2 as an important regulator of megakaryopoiesis, polyploidization, and cytoskeletal dyn

146 ontrast, Tpo-mediated activation of positive megakaryopoiesis regulators such as ERK1/2 and AKT is in

147 ey exhibit an exacerbated mafG deficiency in megakaryopoiesis, specifically in proplatelet formation,

148 may play a GATA-1-independent role in early megakaryopoiesis, suggesting that FOG proteins might act

149 sis toxin did not affect the peak of splenic megakaryopoiesis, supporting the hypothesis that these m

150 pathway of irreversible P-TEFb activation in megakaryopoiesis that is mediated by dissolution of the

151 ns may identify enhancer domains involved in megakaryopoiesis that may be useful in the selective exp

152 insight into regulators of hematopoiesis and megakaryopoiesis that would otherwise be unapparent and

153 nized role for DNM2-dependent endocytosis in megakaryopoiesis, thrombopoiesis, and bone marrow homeos

154 occurs independently of the key regulator of megakaryopoiesis thrombopoietin, and may occur during si

155 Furthermore, megakaryopoiesis was severely impaired in vitro.

156 romosome 21 gene RUNX1, a known regulator of megakaryopoiesis, was not elevated in DS-AMKL.

157 To investigate this process in erythro-megakaryopoiesis, we correlated the genome-wide chromati

158 investigate the role of calcineurin-NFAT in megakaryopoiesis, we examined wild-type mice treated wit

159 consequences of ETS protein misexpression on megakaryopoiesis, we expressed ETS2, ERG, and the relate

160 Using 2 human stem cell models of megakaryopoiesis, we identified novel MK populations cor

161 To further characterize the role of CIB1 in megakaryopoiesis, we used a Cib1(-/-) mouse model.

162 that forms a complex with RUNX1 to regulate megakaryopoiesis, whereas MYH10 persistence was not obse

163 fic requirement for the P1-RUNX1C isoform in megakaryopoiesis, which cannot be entirely compensated f

164 ombocytopenia and an increased extramedullar megakaryopoiesis with an enhanced proportion of prematur